RxDoctor Payments DataLook up a doctor →

Payam Amini, MD

Retina Specialist · Pasadena, CANPI 1205036456

Payments from drug & device makers

$9,892,522in general payments, 2019–2025

Across 1,545 payments — averaging $6402.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$4.9M
  • Regeneron$2M
  • Bayer$1.3M
  • Eyepoint US, Inc.$556K
  • Novartis$463K
  • Hexal AG$195K
  • plus $380K from 31 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.148$4,935,623
Regeneron961$2,030,829
Bayer97$1,331,842
Eyepoint US, Inc.13$556,301
Novartis10$462,933
Hexal AG11$195,215
Ocular Therapeutix, Inc.14$94,403
AbbVie(2 entities)50$67,107
Kyowa Kirin, Inc.11$52,518
Janssen Research & Development, LLC11$52,145
Boehringer Ingelheim International GmbH28$47,533
F. Hoffmann-la Roche AG78$42,921
Roche TCRC, Inc.2$17,235
ANI Pharmaceuticals, Inc.4$1,334
Astellas Pharma US Inc21$676
Bausch & Lomb Americas Inc.6$633
Ivantis, Inc9$530
Alcon9$436
Regeneron Healthcare Solutions, Inc.11$388
Genentech USA, Inc.13$336
Dompe US, Inc.3$316
Alimera Sciences, Inc.4$180
Samsara Vision1$161
Johnson & Johnson Surgical Vision, Inc.2$159
Oyster Point Pharma, Inc.3$151
Apellis Pharmaceuticals, Inc.4$138
Sun Pharmaceutical Industries Inc.5$131
Eyevance Pharmaceuticals LLC3$90
Thea Pharma Inc.3$78
Aerie Pharmaceuticals, Inc.3$59
Glaukos Corporation1$32
Amgen1$24
Spark Therapeutics, Inc.1$20
Tarsus Pharmaceuticals, Inc.1$17
Harrow Eye, LLC1$15
Optos, Inc.1$13
Travere Therapeutics, Inc.1$1

How this compares

$9,892,522 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California →

Medicare billing

Part B allowed, 2024
$983,758
Medicare patients
1,434
Services billed
10,421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other retina specialist in Pasadena

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →